Friday 6-20-2014 Bristol-Myers Squibb Company (BMY
Post# of 115
Posted On: 06/20/2014 10:51:55 PM
Friday 6-20-2014 Bristol-Myers Squibb Company (BMY) $BMY opened at 47.62 hitting the high price of 48.01 and a day low of 47.49 with a total volume of 15,369,121. BMY had a previous close of 47.84 and has been seeing an average volume of 9,286,880.
Overall Average: 48% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - Fri Jun 20, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri Jun 20, 12:26PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri Jun 20, 9:36AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
NYSE Governance Services Announces 2014 Leadership Award Winners
Business Wire - Fri Jun 20, 7:00AM CDT
New York Stock Exchange Governance Services, a subsidiary of Intercontinental Exchange (NYSE: ICE), today announced the winners and finalists of its inaugural Governance, Risk & Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance. (full story)
Emerging Therapies for Previously Treated EGFR Wild-Type/Untested Non-Small-Cell Lung Cancer are Expected to Offer Efficacy Benefits Over Current Treatments
PR Newswire - Thu Jun 19, 11:00AM CDT
Decision Resources Group (DRG) finds that, according to surveyed U.S. and European oncologists, improvement in efficacy endpoints are the most influential factors in prescribing decisions for previously treated EGFR wild-type/untested non-small-cell lung cancer (NSCLC). DRG also finds that improved median overall survival and increased progression-free survival are the greatest unmet needs in this indication. Surveyed oncologists express enthusiasm for PD-1 monoclonal antibody inhibitors and anticipate that Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab and Merck's pembrolizumab will demonstrate efficacy advantages over currently available therapies. Interviewed thought leaders also expressed enthusiasm for AstraZeneca's MEK inhibitor selumetinib in combination with docetaxel (generics) for the treatment of KRAS-mutant patients. (full story)
Alkermes' Aripiprazole Lauroxil Looks Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 10:40AM CDT
Alkermes' (ALKS) aripiprazole lauroxil performed well in a phase III study. (full story)
Bristol-Myers Squibb Set to Possibly Pullback After Yesterday's Rally of 1.26%
Comtex SmarTrend(R) - Wed Jun 18, 3:57PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $47.40 to a high of $48.13. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $47.64 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.26% Gain
Comtex SmarTrend(R) - Wed Jun 18, 3:57PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $47.40 to a high of $48.13. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $47.64 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019
M2 - Wed Jun 18, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bcz55/synthetic_biology) has announced the addition of the "2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019" report to their offering. Synthetic biology defined as the synthesis of artificial or natural components in order to form new artificial living system by re-molding existing biological elements. It aims to attain new preferred functions of artificially modified organisms intended for high yield production of biological systems. Synthetic biology plays an important role in the field of life sciences by developing cheap synthesis procedures. Increasing scientific research coupled with introduction of advanced technologies in synthetic biology will drive the growth of this market. The market for synthetic biology is segmented as: by products, by technologies and by applications. Product segment includes core products and enabling products. Core product segment comprises synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. While enabling products are segmented into DNA and oligonucleotide synthesis products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market, by Products Chapter 5 Global Synthetic Biology Market, by Technologies Chapter 6 Global Synthetic Biology Market, by Applications Chapter 7 Global Synthetic Biology Market, by Geography Chapter 8 Competitive Landscape Chapter 9 Recommendations Chapter 10 Company Profiles Companies Mentioned: - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/9b...ic_biology (full story)
Bristol-Myers Squibb's board to pay dividend on common & preferred stock
M2 - Wed Jun 18, 4:27AM CDT
The board of directors of Bristol-Myers Squibb Company (NYSE:BMY), a biopharmaceutical company, on Tuesday declared its quarterly dividend of USD0.36 per share on its USD0.10 par value common stock. (full story)
Is Roche's Dividend In Danger?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 17, 5:00PM CDT
Swiss giant Roche swims in treacherous waters. The pharmaceutical industry can be a challenging place to operate, as companies must spend $1 billion or more to develop a new drug and a majority of those that are put into... (full story)
Bristol-Myers Squibb Announces Dividend
Business Wire - Tue Jun 17, 3:30PM CDT
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2014, to stockholders of record at the close of business on July 3, 2014. (full story)
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global (full story)
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG (NYSE:NVS), Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb (NYSE:BMY) and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its Board of Directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax Board. (full story)
Overall Average: 48% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - Fri Jun 20, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri Jun 20, 12:26PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri Jun 20, 9:36AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
NYSE Governance Services Announces 2014 Leadership Award Winners
Business Wire - Fri Jun 20, 7:00AM CDT
New York Stock Exchange Governance Services, a subsidiary of Intercontinental Exchange (NYSE: ICE), today announced the winners and finalists of its inaugural Governance, Risk & Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance. (full story)
Emerging Therapies for Previously Treated EGFR Wild-Type/Untested Non-Small-Cell Lung Cancer are Expected to Offer Efficacy Benefits Over Current Treatments
PR Newswire - Thu Jun 19, 11:00AM CDT
Decision Resources Group (DRG) finds that, according to surveyed U.S. and European oncologists, improvement in efficacy endpoints are the most influential factors in prescribing decisions for previously treated EGFR wild-type/untested non-small-cell lung cancer (NSCLC). DRG also finds that improved median overall survival and increased progression-free survival are the greatest unmet needs in this indication. Surveyed oncologists express enthusiasm for PD-1 monoclonal antibody inhibitors and anticipate that Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab and Merck's pembrolizumab will demonstrate efficacy advantages over currently available therapies. Interviewed thought leaders also expressed enthusiasm for AstraZeneca's MEK inhibitor selumetinib in combination with docetaxel (generics) for the treatment of KRAS-mutant patients. (full story)
Alkermes' Aripiprazole Lauroxil Looks Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 10:40AM CDT
Alkermes' (ALKS) aripiprazole lauroxil performed well in a phase III study. (full story)
Bristol-Myers Squibb Set to Possibly Pullback After Yesterday's Rally of 1.26%
Comtex SmarTrend(R) - Wed Jun 18, 3:57PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $47.40 to a high of $48.13. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $47.64 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.26% Gain
Comtex SmarTrend(R) - Wed Jun 18, 3:57PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $47.40 to a high of $48.13. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $47.64 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019
M2 - Wed Jun 18, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bcz55/synthetic_biology) has announced the addition of the "2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019" report to their offering. Synthetic biology defined as the synthesis of artificial or natural components in order to form new artificial living system by re-molding existing biological elements. It aims to attain new preferred functions of artificially modified organisms intended for high yield production of biological systems. Synthetic biology plays an important role in the field of life sciences by developing cheap synthesis procedures. Increasing scientific research coupled with introduction of advanced technologies in synthetic biology will drive the growth of this market. The market for synthetic biology is segmented as: by products, by technologies and by applications. Product segment includes core products and enabling products. Core product segment comprises synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. While enabling products are segmented into DNA and oligonucleotide synthesis products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market, by Products Chapter 5 Global Synthetic Biology Market, by Technologies Chapter 6 Global Synthetic Biology Market, by Applications Chapter 7 Global Synthetic Biology Market, by Geography Chapter 8 Competitive Landscape Chapter 9 Recommendations Chapter 10 Company Profiles Companies Mentioned: - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/9b...ic_biology (full story)
Bristol-Myers Squibb's board to pay dividend on common & preferred stock
M2 - Wed Jun 18, 4:27AM CDT
The board of directors of Bristol-Myers Squibb Company (NYSE:BMY), a biopharmaceutical company, on Tuesday declared its quarterly dividend of USD0.36 per share on its USD0.10 par value common stock. (full story)
Is Roche's Dividend In Danger?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 17, 5:00PM CDT
Swiss giant Roche swims in treacherous waters. The pharmaceutical industry can be a challenging place to operate, as companies must spend $1 billion or more to develop a new drug and a majority of those that are put into... (full story)
Bristol-Myers Squibb Announces Dividend
Business Wire - Tue Jun 17, 3:30PM CDT
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2014, to stockholders of record at the close of business on July 3, 2014. (full story)
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global (full story)
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG (NYSE:NVS), Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb (NYSE:BMY) and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its Board of Directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax Board. (full story) 
(0)
(0)Bristol-Myers Squibb Company (BMY) Stock Research Links
Scroll down for more posts ▼